Macrocyclics pyrimidines as aurora kinase inhibitors
US8815872B2 · kind B2 · utility
16Cited by
0References
5Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Sep 3, 2009 |
| Grant date | Aug 26, 2014 |
| Priority date | — |
| Expiry date | Sep 3, 2029 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC07D515/08
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
Macrocyclic derivative compounds that inhibit protein kinase enzymes are disclosed along with pharmaceutical compositions comprising these compounds and methods for synthesizing the same. Such compounds have utility in the treatment of proliferative diseases resulting from unregulated and/or disturbed kinase activity such as cancers, psoriasis, viral and bacterial infections, inflammatory and autoimmune diseases.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.